Cargando…

In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells

BACKGROUND: Breast cancer treatment is based on a combination of adjuvant chemotherapy followed by radiotherapy effecting intracellular signal transduction. With the tyrosine kinase inhibitors new targeted drugs are available. Imatinib mesylate is a selective inhibitor of bcr-abl, PRGFR alpha, beta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weigel, Marion T, Dahmke, Linda, Schem, Christian, Bauerschlag, Dirk O, Weber, Katrin, Niehoff, Peter, Bauer, Maret, Strauss, Alexander, Jonat, Walter, Maass, Nicolai, Mundhenke, Christoph
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2925350/ https://www.ncbi.nlm.nih.gov/pubmed/20691121 http://dx.doi.org/10.1186/1471-2407-10-412

Ejemplares similares

Sexual Activity as Cause for Non-Surgical Pneumoperitoneum
por: Jacobs, Volker R., et al.
Publicado: (2000)

Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial
por: Wenners, Antonia, et al.
Publicado: (2017)

Periorbital edema secondary to imatinib mesylate
por: McClelland, Collin M, et al.
Publicado: (2010)

Cutaneous adverse effects of imatinib mesylate
por: Dogu, Mehmet Hilmi, et al.
Publicado: (2015)

Imatinib Mesylate-Induced Hyperpigmentation of the Nose and Palate
por: Song, Hyo Sang, et al.
Publicado: (2014)

Imatinib mesylate resistance and mutations: An Indian experience
por: Srivastava, Shweta, et al.
Publicado: (2013)

Lichenoid drug eruption due to imatinib mesylate
por: Bhatia, Anuradha, et al.
Publicado: (2015)

The teratogenic effects of imatinib mesylate on rat fetuses
por: El Gendy, M.M., et al.
Publicado: (2015)

Exacerbation of Psoriasis after Imatinib Mesylate Treatment
por: Shim, Joon Ho, et al.
Publicado: (2016)

Vulvar cancer: epidemiology, clinical presentation, and management options
por: Alkatout, Ibrahim, et al.
Publicado: (2015)

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
por: Din, Omar S, et al.
Publicado: (2008)

The role of c-kit and imatinib mesylate in uveal melanoma
por: Pereira, Patricia Rusa, et al.
Publicado: (2005)

Plantar Keratoderma with Pachyonychia Likely Induced by Imatinib Mesylate
por: Kim, Hyung Ok, et al.
Publicado: (2013)

Ageing is a risk factor in imatinib mesylate cardiotoxicity
por: Maharsy, Wael, et al.
Publicado: (2014)

Molecular Mobility and Stability Studies of Amorphous Imatinib Mesylate
por: Karolewicz, Bożena, et al.
Publicado: (2019)

Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate
por: Pautier, Patricia, et al.
Publicado: (2013)

Imatinib Mesylate-Induced Erythema Multiforme: Recurrence after Rechallenge with 200 mg/day Imatinib
por: Lee, Min Kyung, et al.
Publicado: (2015)

Cysteine‐rich protein 61 regulates the chemosensitivity of chronic myeloid leukemia to imatinib mesylate through the nuclear factor kappa B/Bcl‐2 pathway
por: Song, Yanfang, et al.
Publicado: (2019)

Phase II trial of imatinib mesylate in patients with metastatic melanoma
por: Kim, K B, et al.
Publicado: (2008)

Metastatic duodenal GIST: role of surgery combined with imatinib mesylate
por: Mohiuddin, Kamran, et al.
Publicado: (2007)

ZNF-Mediated Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumor
por: Rink, Lori, et al.
Publicado: (2013)

Generalized Lichenoid Drug Eruption Associated with Imatinib Mesylate Therapy
por: Ghosh, Sudip Kumar
Publicado: (2013)

Preclinical evaluation of Sunitinib as a single agent in the prophylactic setting in a mouse model of bone metastases
por: Schem, Christian, et al.
Publicado: (2013)

Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis
por: Dufresne, A, et al.
Publicado: (2010)

Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia
por: Hu, Zheng, et al.
Publicado: (2009)

Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec™)
por: Cho, Ah Young, et al.
Publicado: (2011)

Optimal Duration of Imatinib Mesylate Therapy in Metastatic Gastrointestinal Stromal Tumours
por: Gauden, Ruth, et al.
Publicado: (2011)

Imatinib Mesylate-Induced Cutaneous Rash Masquerading as Pityriasis Rosea of Gilbert
por: Verma, Prashant, et al.
Publicado: (2014)

Complete pathological response to Imatinib mesylate in an extraintestinal gastrointestinal stromal tumor
por: Quezada, Nicolás, et al.
Publicado: (2014)

Lichenoid Drug Eruption after Low-Dose Imatinib Mesylate Treatment
por: Lee, Jae-Hyung, et al.
Publicado: (2013)

Effects of imatinib mesylate on pulmonary allergic vasculitis in a murine model
por: Suzuki, Naomi, et al.
Publicado: (2013)

Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase
por: Linga, Vijay Gandhi, et al.
Publicado: (2014)

Molecular response to imatinib mesylate of Brazilian patients with chronic myeloid leukemia
por: Vieira-Mion, Ana Lucia, et al.
Publicado: (2017)

Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
por: Tang, Sumin, et al.
Publicado: (2017)

Effects of imatinib mesylate on cutaneous neurofibromas associated with neurofibromatosis type 1
por: Yasuda, Ken‐ichi, et al.
Publicado: (2020)

Kaposi’s sarcoma associated with chronic myeloid leukemia and imatinib mesylate therapy
por: D’Addona, Matteo, et al.
Publicado: (2022)

Injectable Gamboge-Based In Situ Gel for Sustained Delivery of Imatinib Mesylate
por: Jitrangsri, Kritamorn, et al.
Publicado: (2023)

The Merendino procedure following preoperative imatinib mesylate for locally advanced gastrointestinal stromal tumor of the esophagogastric junction
por: Staiger, Wilko I, et al.
Publicado: (2008)

Imatinib Mesylate: Past Successes and Future Challenges in the Treatment of Gastrointestinal Stromal Tumors
por: Ksienski, Doran
Publicado: (2011)

Delivery as nanoparticles reduces imatinib mesylate-induced cardiotoxicity and improves anticancer activity
por: Marslin, Gregory, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_bg2paiq2mgcmf29sg1fu121k17